Myeloma Paper of the Day, May 10th, suggested by Robert Orlowski

Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day: Prospective biomarker study finds preexisting cytopenias and hyperferritinemia predict long duration of post-CAR T-cell cytopenias, which may relate to immune remodeling with shift in CAR-negative T-cell subsets following therapy.”

Source: Robert Orlowski/X

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Authors: Xiang Zhou, Vivien Wagner, Lukas Scheller, Emilia Stanojkovska, Christine Riedhammer, Xianghui Xiao, Maximilian Johannes Steinhardt, Cornelia Vogt, Silvia Nerreter, Florian Eisele, Mara John, Umair Munawar, Sofie-Katrin Kadel, Julia Mersi, Anna Ruckdeschel, Sven Schimanski, Larissa Haertle, Johannes Waldschmidt, Seungbin Han, Max Topp, Johannes Duell, Hermann Einsele, Angela Riedel, K. Martin Kortüm, and Leo Rasche.

Other insights by Robert Orlowski on OncoDaily.